Reaction profile
The FDA adverse-event record for dermatophytosis
20 FDA reports name dermatophytosis, a lower-volume reaction in the CVM extract (VeDDRA 1406). Plate stamps and neighbourhood peers follow.
- #2160 of 2,481
- by report volume (all reactions)
- 20
- reports citing this reaction
- 0.0%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Dermatophytosis has 20 reports now versus 20 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Dermatophytosis changesFDA AER · VeDDRA plate
Code 1406 VOL-TRACE
VOL-TRACE · DEATH-RARE · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-TRACE 20 reports
- DEATH-RARE 0.0%
- LOWER-Q #2160/2481
- PHOTO-FINISH Agalactia
- SPECIES-DOG Dog · 16
- DRUG-LEAD Milbemycin Oxime… · 7
- DESK-WIDE 14 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Agalactia (±0 reports)
Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.
Lower-volume neighbourhood around Dermatophytosis
Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.
Dermatophytosis: low death-coded share in the FDA AER plate
Signature read: Dermatophytosis's 0.0% death-coded share is among the lowest in the openFDA reaction corpus. Report volume is lower-third scale: 20 named reports in the openFDA extract. Death-coded share is lower-third: 0 of 20 reports (0.0% of named reports). Nearest volume peer: Agalactia (±0 reports). Lead species Dog (16). Lead co-reported drug Milbemycin Oxime + Spinosad (7).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Milbemycin Oxime + Spinosad appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
What to do with this reaction
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →